ID

22314

Description

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Concomitant Medications Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Link

https://clinicaltrials.gov/ct2/show/NCT00078572

Keywords

Versions (1)
  1. 5/29/17 5/29/17 -
Uploaded on

May 29, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Concomitant Medications NCT00078572

English

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Concomitant Medications NCT00078572

1 forms  
Concomitant Medications
Description

Concomitant Medications

Alias
UMLS CUI-1
C2347852
Drug, Trade name preferred
Description

Drug

Data type

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C2360065
Date started
Description

Date started

Data type

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C2347852
Check if started Pre-study
Description

started Pre-study

Data type

text

Alias
UMLS CUI [1]
C2347852
Date stopped
Description

Date stopped

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C2347852
Check if continued Post- study
Description

continued Post- study

Data type

text

Alias
UMLS CUI [1]
C2347852
Conditions treated/ indication
Description

Conditions treated or indication

Data type

text

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C2347852
Back to the top of the page

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Concomitant Medications NCT00078572

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Concomitant Medications
C2347852 (UMLS CUI-1)
Drug
Item
Drug, Trade name preferred
text
C2347852 (UMLS CUI [1,1])
C2360065 (UMLS CUI [1,2])
Date started
Item
Date started
date
C0808070 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Item
Check if started Pre-study
text
C2347852 (UMLS CUI [1])
started Pre-study
Code List
Check if started Pre-study
CL Item
Yes (Y)
CL Item
No (N)
Date stopped
Item
Date stopped
date
C0806020 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Item
Check if continued Post- study
text
C2347852 (UMLS CUI [1])
started Pre-study
Code List
Check if continued Post- study
CL Item
Yes (Y)
CL Item
No (N)
Conditions treated or indication
Item
Conditions treated/ indication
text
C3146298 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial